Order Article Reprints

Tang Y, Zhong M, Pan G, Tan J, Xie C, Jiang Y, Yao J, Shan W, Lin J, Huang J, et al. Preclinical Studies of Chiauranib Show It Inhibits Transformed Follicular Lymphoma through the VEGFR2/ERK/STAT3 Signaling Pathway. Pharmaceuticals. 2023; 16(1):15. https://doi.org/10.3390/ph16010015

Tang, Yuanfang, Mengya Zhong, Guangchao Pan, Jinshui Tan, Chendi Xie, Yuelong Jiang, Jingwei Yao, Weihang Shan, Jiaqi Lin, Jiewen Huang, and et al. 2023. "Preclinical Studies of Chiauranib Show It Inhibits Transformed Follicular Lymphoma through the VEGFR2/ERK/STAT3 Signaling Pathway" Pharmaceuticals 16, no. 1: 15. https://doi.org/10.3390/ph16010015

Tang, Y., Zhong, M., Pan, G., Tan, J., Xie, C., Jiang, Y., Yao, J., Shan, W., Lin, J., Huang, J., Liu, Y., Li, Z., Xu, B., & Zha, J. (2023). Preclinical Studies of Chiauranib Show It Inhibits Transformed Follicular Lymphoma through the VEGFR2/ERK/STAT3 Signaling Pathway. Pharmaceuticals, 16(1), 15. https://doi.org/10.3390/ph16010015